Routine

Complement deficiency — recurrent Neisseria infection workup

Terminal/alternative complement defects and meningococcal risk · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Deficiencies of the terminal complement components (C5-C9) and the alternative pathway predispose to recurrent or unusual Neisseria infections, including recurrent meningococcal disease with non-groupable strains. Identifying the defect allows targeted vaccination and antibiotic prophylaxis to prevent life-threatening infection.

Red flags

  • Recurrent meningococcal disease, especially non-groupable/unusual serogroups
  • Family history of recurrent Neisseria infection
  • Fulminant sepsis with purpura
  • Disseminated gonococcal infection without obvious risk
  • Absent CH50 or AP50 on screening

Assessment

Differential diagnosis

  • Terminal complement (C5-C9) deficiency
  • Properdin / alternative pathway deficiency
  • Early classical complement (C1-C4) deficiency (more lupus-like)
  • Asplenia / hyposplenism
  • Antibody deficiency (CVID / specific antibody deficiency)

Investigations

  • CH50 (classical pathway) and AP50/AH50 (alternative pathway) screening — both guide the defect
  • Individual complement component assays if screen abnormal
  • Blood cultures and CSF culture/PCR during acute infection with serogrouping
  • Immunoglobulins and vaccine responses to exclude antibody deficiency
  • Properdin level (X-linked) if alternative pathway low

Management

  • Suspect complement deficiency after recurrent, familial or unusual-serogroup Neisseria infection
  • Treat acute meningococcal disease promptly with empirical ceftriaxone
  • Screen with CH50 and AP50 — an absent CH50 points to classical/terminal defects, absent AP50 to alternative pathway
  • Confirm the specific component with individual assays
  • Vaccinate against meningococcus (ACWY and B), pneumococcus and Haemophilus influenzae type b
  • Start long-term antibiotic prophylaxis in terminal complement deficiency
  • Advise prompt assessment and early antibiotics for any febrile illness
  • Screen family members and refer to clinical immunology

Drugs & doses

Ceftriaxone — 2 g IV every 12 hours for acute meningococcal disease
Phenoxymethylpenicillin — 250-500 mg orally twice daily for long-term prophylaxis
Meningococcal ACWY conjugate vaccine and meningococcal B vaccine — per schedule
Benzylpenicillin — 1.2 g IM pre-hospital if meningococcal disease suspected with delay to hospital

Disposition

Refer to clinical immunology for confirmation, vaccination and prophylaxis; admit acute invasive infection.

Complications & pitfalls

  • Recurrent invasive meningococcal disease
  • Meningitis and septic shock
  • Delay to diagnosis due to normal routine immunology
  • Incomplete vaccine protection against non-vaccine serogroups
  • Transmission risk and family cases

Exam pearls

  • Measure both CH50 and AP50 — a defect may only show in one pathway
  • Terminal complement deficiency presents with recurrent meningococcaemia, often milder and with rare serogroups
  • Vaccination and antibiotic prophylaxis dramatically reduce infection risk
  • Screen and counsel family members, as many defects are inherited

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.